Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dbv Technologies SA is conducting a Phase 3 clinical trial titled ‘Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers).’ The study aims to evaluate the safety of the DBV712 250 mcg patch in young children with peanut allergies over a six-month period. This research is significant as it could lead to a new treatment option for peanut allergies in a vulnerable age group.
The intervention being tested is the DBV712 250 mcg epicutaneous patch, designed to deliver small doses of peanut protein through the skin to build tolerance in allergic children. A placebo patch is also used for comparison.
The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish the safety of the DBV712 patch.
The study began on June 24, 2025, with primary completion expected after six months. The last update was on August 5, 2025. These dates are crucial as they guide the timeline for potential market entry and investor expectations.
This clinical update could positively impact Dbv Technologies’ stock performance by boosting investor confidence in the company’s innovative approach to treating peanut allergies. The study’s progress may also influence the competitive landscape, as other companies in the allergy treatment sector monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.